EPHA2 and neoplasm: Consistently, this tumor‐suppressive EphA2 axis was most prevalent in the untreated cisplatin‐sensitive TYK‐nu, while the acute TYK‐nu.R sensitivity to LJH685 was coupled with increased EphA2‐pY588 (Fig 5C and D; NA after collapsed cell viability by combinatorial treatment).